Abstract
In the current study, a highly porous β-CD-metal organic frameworks (βCD-MOFs) was prepared and drug, olaparib (OP) was loaded successfully in order to enhance the efficacy of OP for the treatment of cervical cancer. The produced OP-loaded βCD-MOFs were assessed using TC-1 cell lines for drug encapsulation, FTIR, DSC, TGA, PXRD, in vitro release studies, SEM, and MTT assay. βCD-MOFs successfully encapsulated the OP with a high efficiency of 76.48%, due to structural advantages of βCD-MOFs. In-vitro release studies exhibited a sustained release pattern for 24 h. As compared to free-OP, we observed a significant reduction in cell viability and lowered inhibitory concentration IC50 (13.52 nM) in TC-1 cells treated with OP-loaded βCD-MOFs. Additionally, p53 and caspase 9 were elevated by the OP-loaded βCD-MOFs, suggesting an effective apoptosis that may hold promise for the therapy of cervical cancer. Overall, OP-loaded βCD-MOFs could be alternative to conventional formulation of OP in treating cervical cancer.
Data availability
All the data generated in this study have been included in the manuscript.
References
Hull, R. et al. Cervical cancer in low and middle-income countries. Oncol. Lett. 20, 2058–2074. https://doi.org/10.3892/ol.2020.11754 (2020).
Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 74, 229–63. https://doi.org/10.3322/caac.21834 (2024).
Burd, E. M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 16, 1–17. https://doi.org/10.1128/CMR.16.1.1-17.2003 (2003).
Okunade, K. S. Human papillomavirus and cervical cancer. J. Obstet. Gynaecol. 40(5), 602–608. https://doi.org/10.1080/01443615.2019.1634030 (2020).
PDQ Cancer Information Summaries. Cervical Cancer Treatment: Patient Version. https://www.ncbi.nlm.nih.gov/books/NBK65985/ (National Cancer Institute (US), 2002).
Burmeister, C. A. et al. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 13, 200238. https://doi.org/10.1016/j.tvr.2022.200238 (2022).
Ranasinghe, V. & McMillan, N. Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer. Crit. Rev. Oncol. Hematol. 211, 104721. https://doi.org/10.1016/j.critrevonc.2025.104721 (2025).
Zhang, C., Xu, C., Gao, X. & Yao, Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 12, 2115–2132. https://doi.org/10.7150/thno.69424 (2022).
Florea, A. M. & Büsselberg, D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3, 1351–71. https://doi.org/10.3390/cancers3011351 (2011).
Bondar, D. & Karpichev, Y. Poly(ADP-Ribose) polymerase (PARP) inhibitors for cancer therapy: Advances, challenges, and future directions. Biomolecules 14, 1269. https://doi.org/10.3390/biom14101269 (2024).
Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L. & Ming, H. V. Y. PARP inhibitors in breast and ovarian cancer. Cancers (Basel) 15, 2357. https://doi.org/10.3390/cancers15082357 (2023).
Bianchi, A. et al. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol. Oncol. 155, 144–150. https://doi.org/10.1016/j.ygyno.2019.08.010 (2019).
Montero-Macias, R. et al. Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: A case report. J. Med. Case Rep. 15, 210. https://doi.org/10.1186/s13256-021-02767-9 (2021).
Alali, A. S. et al. Nanocrystallization improves the solubilization and cytotoxic effect of a poly (ADP-Ribose)-polymerase-I inhibitor. Polymers (Basel) 14(22), 4827. https://doi.org/10.3390/polym14224827 (2022).
Anwer, M. K. et al. Development of chitosan-coated PLGA-based nanoparticles for improved oral olaparib delivery: In vitro characterization, and in vivo pharmacokinetic studies. Processes 10(7), 1329. https://doi.org/10.3390/pr10071329 (2022).
Yun, T. et al. Investigation of stabilized amorphous solid dispersions to improve oral olaparib absorption. Pharmaceutics 16(7), 958. https://doi.org/10.3390/pharmaceutics16070958 (2024).
Kim, Y. H. et al. Development and evaluation of self-microemulsifying drug delivery system for improving oral absorption of poorly water-soluble olaparib. Pharmaceutics 15(6), 1669. https://doi.org/10.3390/pharmaceutics15061669 (2023).
Li, Z. et al. Advances in biocompatible metal-organic frameworks for biomedical applications. Adv. Mater. e2503946. https://doi.org/10.1002/adma.202503946 (2025).
Liu, B. et al. Optimized synthesis and crystalline stability of γ-cyclodextrin metal-organic frameworks for drug adsorption. Int. J. Pharm. 514(1), 212–219. https://doi.org/10.1016/j.ijpharm.2016.09.029 (2016).
Khafaga, D. S. R. et al. Metal-organic frameworks in drug delivery: Engineering versatile platforms for therapeutic applications. RSC Adv. 14, 30201–30229. https://doi.org/10.1039/d4ra04441j (2024).
Rajamohan, R. et al. Adenosine/β-Cyclodextrin-based metal–organic frameworks as a potential material for cancer therapy. Biomolecules 13, 1154. https://doi.org/10.3390/biom13071154 (2023).
Wei, Y. et al. Enrofloxacin/florfenicol loaded cyclodextrin metal-organic-framework for drug delivery and controlled release. Drug Deliv. 28(1), 372–379. https://doi.org/10.1080/10717544.2021.1879316 (2021).
Sadeh, P., Zeinali, S., Rastegari, B. & Najafipour, I. Functionalization of β-cyclodextrin metal-organic frameworks with gelatin and glutamine for drug delivery of curcumin to cancerous cells. Heliyon 10(9), e30349. https://doi.org/10.1016/j.heliyon.2024.e30349 (2024).
Bakht, M. A., Alharthi, A. I. & Ali, M. I. Fabrication of zeolite-supported cobalt ferrite (CoFe2O4/ H-zsm-5) catalyst for the synthesis of 4-(9-(4-substituted)-1,2,3,4,5,6,7,8-octahydro-3,3,6,6-tetramethyl-1,8-dioxoacridin-10(9H)-yl)benzoic acid derivatives in semi aqueous condition. J. Phys. Chem. Solids 193, 112169. https://doi.org/10.1016/j.jpcs.2024.112169 (2024).
Anwer, M. K. et al. Preparation of sustained release apremilast-loaded PLGA nanoparticles: In vitro characterization and in vivo pharmacokinetic study in rats. Int. J. Nanomedicine 14, 1587–1595. https://doi.org/10.2147/IJN.S195048 (2019).
Raish, M. et al. Photodynamic therapy in combination with green tea polyphenols EGCG enhances antitumor efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells. J Appl Res 10, 58–67 (2010).
Aljuffali, I. A. et al. Development of Gefitinib-loaded solid lipid nanoparticles for the treatment of breast cancer: Physicochemical evaluation, stability, and anticancer activity in breast cancer (MCF-7) cells. Pharmaceuticals 16, 1549. https://doi.org/10.3390/ph16111549 (2023).
Wang, S. et al. Covering soy polysaccharides gel on the surface of β-cyclodextrin-based metal–organic frameworks. J. Mater. Sci. 56, 3049–3061. https://doi.org/10.1007/s10853-020-05491-9 (2021).
Nurazzi, N. M. et al. Thermogravimetric analysis properties of cellulosic natural fiber polymer composites: A review on influence of chemical treatments. Polymers 13(16), 2710. https://doi.org/10.3390/polym13162710 (2021).
Qiu, C. et al. Green synthesis of cyclodextrin-based metal-organic frameworks through the seed-mediated method for the encapsulation of hydrophobic molecules. J. Agric. Food Chem. 66, 4244–4250. https://doi.org/10.1021/acs.jafc.8b00400 (2018).
Bahmani, B., Amini-Bayat, Z., Ranjbar, M. M., Makoui, M. H. & Zarnani, A. H. Development and evaluation of a novel E7 multi-epitopic vaccine for human papillomavirus type 16: Design, expression, purification, and immunological characterization. BMC Infect. Dis. 25, 174. https://doi.org/10.1186/s12879-024-10343-x (2025).
Xu, X. & Wang, C. Evaluation of drug loading capabilities of γ-cyclodextrin-metal organic frameworks by high performance liquid chromatography. J. Chromatogr. A. 1488, 37–44. https://doi.org/10.1016/j.chroma.2017.01.062 (2017).
Liu, D. & Guo, Y. Inclusion of lycorine with natural cyclodextrins (α-, β- and γ-CD): Experimental and in vitro evaluation. J. Mol. Struct. 1130, 669–676 (2017).
Iliya, K. & Tatyana, V. Methotrexate-loaded metal-organic frameworks on the basis of γ-cyclodextrin: Design, characterization, in vitro and in vivo investigation. Mater. Sci. Eng. C 111, 110774. https://doi.org/10.1016/j.msec.2020.110774 (2020).
Xiong, Y., Wu, L. & Guo, T. Crystal transformation of β-CD-MOF facilitates loading of dimercaptosuccinic acid. AAPS Pharm. Sci. Tech 20, 224. https://doi.org/10.1208/s12249-019-1422-z (2019).
Yamakawa, N. et al. High LET radiation enhances apoptosis in mutated p53 cancer cells through caspase-9 activation. Cancer Sci. 99, 1455–60. https://doi.org/10.1111/j.1349-7006.2008.00818.x (2008).
Cui, H., Schroering, A. & Ding, H. F. p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol. Cancer Ther. 1(9), 679–686 (2002).
Vousden, K. H. & Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8(4), 275–283 (2007).
Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 35 (4), 495–516 (2007).
Kim, Y. W., Bae, S. M., Battogtokh, G., Bang, H. J. & Ahn, W. S. Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: In vivo and in vitro studies. PLoS One. 7 (6), e38583 (2012).
Rastegar, R. et al. Evaluation of a novel biocompatible magnetic nanomedicine based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast cancer. Artif. Cells Nanomed. Biotechnol. 46(sup2), 207–216 (2018).
Wu, G. S. & Ding, Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21(1), 1–8 (2002).
Yamakawa, N. et al. High LET radiation enhances apoptosis in mutated p53 cancer cells through Caspase-9 activation. Cancer Sci. 99(7), 1455–1460 (2008).
Acknowledgements
The authors extend their appreciation to Prince Sattam bin Abdulaziz University for funding this research work through the project number PSAU/2024/31664.
Funding
The authors extend their appreciation to Prince Sattam bin Abdulaziz University for funding this research work through the project number PSAU/2024/31664.
Author information
Authors and Affiliations
Contributions
Conceptualization, B.B.A. and M.K.A.; methodology, M.N.H. and M.K.A.; software, M.R.; validation, M.K.A.; formal analysis, M.K.A. M.R; investigation, B.B.A. and M.K.A.; resources, M.K.A.; data curation, M.K.A.; writing—original draft preparation, M.K.A. and M.N.H; writing—review and editing, M.N.H. and M.K.A.; supervision, M.K.A.; project administration, M.K.A.; funding acquisition, M.K.A. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Alsulays, B.B., Anwer, M.K., Hatata, M.N. et al. Development of β-CD metal organic frameworks loaded with olaparib: a novel approach for the treatment of cervical cancer. Sci Rep (2026). https://doi.org/10.1038/s41598-026-43779-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-43779-z
